By the same authors

From the same journal

From the same journal

In Vivo Bioluminescence Imaging to Assess Compound Efficacy Against Trypanosoma brucei

Research output: Contribution to journalArticlepeer-review

Published copy (DOI)

Author(s)

Department/unit(s)

Publication details

JournalMethods in Molecular Biology
DateAccepted/In press - 2019
DatePublished (current) - 2020
Volume2116
Number of pages17
Pages (from-to)801-817
Original languageEnglish

Abstract

Traditional animal models for human African trypanosomiasis rely on detecting Trypanosoma brucei brucei parasitemia in the blood. Testing the efficacy of new compounds in these models is cumbersome because it may take several months after treatment before surviving parasites become detectable in the blood. To expedite compound screening, we have used a Trypanosoma brucei brucei GVR35 strain expressing red-shifted firefly luciferase to monitor parasite distribution in infected mice through noninvasive whole-body bioluminescence imaging. This protocol describes the infection and in vivo bioluminescence imaging of mice to assess compound efficacy against T. brucei during the two characteristic stages of disease, the hemolymphatic phase (stage 1) and the encephalitic or central nervous system phase (stage 2).

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations